At the archive date, AbbVie Inc. was expected to release its Q3 2026 10-Q filing on October 29, 2026. Last quarter: AbbVie's Q2 FY2026 results showcased strong double-digit revenue growth driven by immunology products, while net income soared due to reduced non-cash charges, though Humira decline and regulatory risks remain.
EPS Estimate
$3.92
Revenue Estimate
$17.65B
Analyst consensus captured from Finnhub and Financial Modeling Prep. This archived preview is no longer updated with later results; see the ABBV page for retained reports.
Drawn from management commentary in the Q2 2026 10-Q:
Skyrizi net revenues increased 24% on a constant currency basis for the quarter, while Rinvoq grew 24%, both driven by strong market share gains and market expansion across indications, more than offsetting Humira's 36% decline due to biosimilar erosion.
Net income surged 285% YoY partly because the fair value charge on contingent consideration liabilities decreased by $1.3 billion compared to the year-ago quarter, reflecting higher estimated Skyrizi sales and favorable pipeline developments.
AbbVie achieved several regulatory wins, including FDA approvals for Skyrizi in pediatric psoriasis, Venclexta combination for CLL, and Decnupaz for BPDCN, while also submitting applications for Rinvoq in vitiligo and alopecia areata.
Revenue
$16.99B
+10.16% YoY
EPS (Diluted)
$2.03
+290.38% YoY
Operating Income
$6.43B
+31.43% YoY
Add ABBV to your watchlist to keep its archived reports easy to find. New filing alerts are no longer sent.